Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Bernstein SocGen Group has raised its price target on Boston Scientific (NYSE:BSX) to $130.00 from $124.00 while maintaining an Outperform rating. The stock, currently trading near its 52-week high of $108.94, has delivered an impressive year-to-date return of 20.64%. InvestingPro data reveals 16 analysts have recently revised their earnings estimates upward for the upcoming period.
The price target increase follows Boston Scientific’s strong quarterly performance, with Q2 sales growing 17.4% organically. The company’s electrophysiology (EP) division showed remarkable 94% growth driven by Farapulse, while Watchman grew 28% fueled by an increase in concomitant procedures.
All eight business units across Boston Scientific’s Cardiovascular and MedSurg segments exceeded expectations. Both sales and adjusted EPS beat analyst estimates by approximately 3.5%.
Bernstein’s new price target is based on a price-to-earnings multiple of 35.5x against its forward Q5-Q8 EPS estimate of $3.67, which was raised from the previous $3.50.
The research firm sees continued upside potential for Boston Scientific as Farapulse, Watchman and concomitant procedures drive strong performance, with additional growth expected as earlier-stage investments mature.
In other recent news, Boston Scientific reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share of $0.75, compared to the forecast of $0.73. The company also reported revenue of $5.06 billion, exceeding the anticipated $4.89 billion. Wells Fargo (NYSE:WFC) highlighted the company’s strong performance, noting significant momentum in its Pulse Field Ablation technology and increased adoption of the Watchman device, which contributed to a 17.4% organic growth in sales. UBS also raised its price target for Boston Scientific to $135, citing strong product cycles and sales performance that exceeded expectations. Mizuho (NYSE:MFG) increased its price target to $140, maintaining an Outperform rating, due to strong performance in the FARAPULSE and WATCHMAN product lines. BofA Securities adjusted its price target to $120, following an analysis of the company’s second-quarter financial results. These developments reflect a positive outlook from various analysts regarding Boston Scientific’s recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.